Dendreon Corp. (NASDAQ:DNDN) Pumps up on Rating Upgrade

Dendreon Corp. (NASDAQ:DNDN) shares pumped up Friday after a rating upgrade by a Bernstein expert who sees a cheerful future for the firm’s prostate cancer cure drug, Provenge.

Expert Geoffrey Porges lifted the Seattle biotechnology firm to “Outperform” and lifted his price target to $10 from $7 formed on recent feedback from urologists regarding rival drugs.

Dendreon estimated higher than predicted 4Q revised revenue in the start of this week, mentioning that Provenge is beginning to be used more often in community oncology and urology practices.

Its competitors include Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) that surged +2.10% to $3.41 with the total traded volume of 122,797.00shares and Sanofi SA (ADR) (NYSE:SNY) that increased +0.87% to $48.87 with the total traded volume of 1.48 million shares.

Other Healthcare stocks with bullish trend include Merck & Co., Inc. (NYSE:MRK) up 1.05% to $43.23, AbbVie Inc (NYSE:ABBV) up 0.74% to $33.85 and Boston Scientific Corporation (NYSE:BSX) up 0.95% to $6.36, whereas with bearish trend include Pfizer Inc. (NYSE:PFE) down -0.90% to $26.52, UnitedHealth Group Inc. (NYSE:UNH) down -0.55% to $52.82 and Abbott Laboratories (NYSE:ABT) down -1.01% to $33.37.

Dendreon Corporation (NASDAQ:DNDN) stock in last session held volume of 31.70 million shares as compare to its average volume of 4.97 million shares. The stock after opening at $5.80 hit high price of $6.24 and then closed at $6.17 by scoring +20.98%.

As the revenue measures DNDN generated revenue of 442.18 million in the following twelve months income of -$316.82 million. The Company showed a negative -71.65% in the net profit margin and in addition to in its operating margin which remained -59.60%. Company’s annual sales growth for the past five year was +316.37%.

The stock showed weekly upbeat performance of +2.66% which was maintained for the month at +25.41%. Likewise the positive performance for the quarter was recorded as +38.96% and for the year was -51.91% while the YTD performance remained at +16.64%.

The DNDN past twelve months price to sales ratio was 2.15 and price to cash ratio remained 2.44. As far as the returns are concern, the DNDN return on equity was recorded as -176.03% and increased -62.83% return on investment while its return on asset stayed at -37.48%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.